Full-Time

Chicago Graduate Trader Programme 2026

Posted on 10/31/2025

Maven Securities

Maven Securities

201-500 employees

Proprietary-capital multi-strategy trading and market making

Compensation Overview

$150k - $200k/yr

Chicago, IL, USA

In Person

Initial 3-month training in London; relocation to Chicago after training.

Category
Finance & Banking (1)
Required Skills
Python
R
SQL
C#
C/C++
VBA
Requirements
  • You must currently have the right to work in the United States.
  • You are a final year undergraduate student or a final year masters student.
  • Strong numeracy and a good understanding of probability and statistics.
  • Competitive nature and a curiosity to learn with a keen interest in financial markets.
  • Excellent analytical skills with the ability to solve problems creatively.
  • Good communication skills and drive to work collaboratively.
  • Familiarity with programming languages such as Python, VBA, SQL, R, C++, or C#.
Responsibilities
  • The programme involves completing an intensive training programme including theory training, education sessions, live-market trading, and programming courses.
  • The aim is to give you responsibility for the profit and loss of your book as soon as you are ready.
  • You will relocate to our Chicago office to join Options Market Making trading desks after completing training.
  • Opportunity to execute live trades within 3 months of starting.

Maven Securities trades and provides market liquidity across global financial markets using its own capital. It combines fundamental and quantitative methods to find trading opportunities and to execute trades efficiently from front office to settlements. The firm differentiates itself by using exclusively proprietary capital, strong risk controls, and a focus on technology to improve execution. Its goal is to earn sustainable profits while keeping markets liquid for institutional clients and other traders.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • MBX Biosciences' canvuparatide shows 63% Phase 2 response rate, targeting $61 stock.
  • Stifel and UBS issue Buy ratings on MBX with $50-$60 targets for pipeline progress.
  • Maven allocates internal capital flexibly, ensuring alignment and robust returns always.

What critics are saying

  • MBX 4291 Phase 1b obesity data fails in Q4 2026, wiping biotech investment value.
  • Canvuparatide Phase 3 stalls within 12 months, collapsing MBX's lead program valuation.
  • MBX exhausts cash runway in 18 months, forcing dilutive raises that shrink Maven's stake.

What makes Maven Securities unique

  • Deploys proprietary capital across discretionary, systematic, and market-making strategies.
  • Integrates machine learning and cutting-edge tech for algorithmic trading excellence.
  • Provides liquidity in global listed derivatives with tight pricing during volatility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401K Scheme

25 Days Annual Leave plus public holidays

Healthcare, Dental & Vision

Employee Volunteering Opportunities

Annual Discretionary Bonus

Company News

MarketBeat
Aug 21st, 2025
Maven Securities LTD Invests $4 Million in StandardAero, Inc. $SARO

Maven Securities LTD has invested approximately $4 million in StandardAero, acquiring a stake of 150,000 shares as of the first quarter of 2023.

ETF Daily News
Apr 2nd, 2025
Corebridge Financial Inc. Has $2.37 Million Stock Position in Sotera Health (NASDAQ:SHC)

Maven Securities LTD acquired a new stake in Sotera Health in the 3rd quarter valued at approximately $1,670,000.

MarketBeat
Mar 2nd, 2025
Rithm Capital Corp. (NYSE:RITM) Shares Sold by Y Intercept Hong Kong Ltd

Soros Fund Management LLC acquired a new stake in Rithm Capital in the 3rd quarter valued at about $23,835,000.

MarketBeat
Jan 19th, 2025
Rithm Capital Corp. (NYSE:RITM) Receives $12.94 Consensus Price Target from Brokerages

Finally, Maven Securities LTD purchased a new stake in Rithm Capital in the 3rd quarter worth about $11,350,000.

ETF Daily News
Dec 18th, 2024
Wellington Management Group LLP Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

Maven Securities LTD purchased a new stake in Wave Life Sciences in the third quarter worth $6,970,000.

INACTIVE